Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations

Opinion
Video

Vinay Raja, MD, explores the management of patients with Stage-III disease and actionable EGFR/ALK aberrations, as well as the treatment approach for patients with PD-L1 <1%.

Recent Videos
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Related Content
Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC

Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC

Kristi Rosa
June 3rd 2025
Article

Results from CheckMate-816 could be practice-changing after an OS improvement was noted with NAT nivolumab plus chemotherapy in resectable NSCLC.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Efficacy and biomarker analyses from CheckMate-77T support perioperative nivolumab as an effective option in resectable NSCLC.

Nivolumab Extends EFS Across Resectable NSCLC Subgroups

Caroline Seymour
June 3rd 2025
Article

Efficacy and biomarker analyses from CheckMate-77T support perioperative nivolumab as an effective option in resectable NSCLC.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Most patients who received COCOON dermatologic management reported mild or no dermatologic symptoms following treatment with amivantamab/lazertinib.

Dermatologic Management Sustains QOL After Amivantamab Combo in EGFR+ NSCLC

Russ Conroy
June 2nd 2025
Article

Most patients who received COCOON dermatologic management reported mild or no dermatologic symptoms following treatment with amivantamab/lazertinib.

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

Tim Cortese
June 2nd 2025
Article

Neoadjuvant alectinib met the primary end point with a major pathologic response rate of 42% in patients with potentially resectable, stage III NSCLC.